Background. The objective of this study was to investigate purine nucleotide metabolism in peripheral blood mononuclear cells (PBMC) of cardiac transplant recipients switched from azathioprine to mycophenolate mofetil (MMF). Methods. Concentrations of guanosine 5Јtriphosphate (GTP) and adenosine 5Јtriphosphate (ATP), the activities of inosine monophosphate dehydrogenase (IMPDH), guanine phosphoribosyltransferase (GPRT), and hypoxanthine phosphoribosyltransferase (HPRT) were determined in PBMC of 27 cardiac transplant recipients before switch to MMF and 3, 6, and 12 months thereafter.
M ycophenolate mofetil (MMF) is an immunosuppressive agent widely used in combination with calcineurin inhibitors and steroids in patients who underwent cardiac transplantation. Data from a randomized trial demonstrated a significant benefit in 1-year mortality for MMF-treated cardiac recipients compared to azathioprine-treated (1) . The switch from azathioprine to MMF with following stepwise reduction of cyclosporine A dosage led to stabilization and improvement of kidney function in long-term cardiac recipients with calcineurin inhibitor-induced nephropathy (2) . Although no drug regimen associated with increased posttransplant lymphoproliferative disease was identified in retrospective analysis (3) , the use of MMF seemed to be associated with a reduction of posttransplant lymphomas in kidney recipients. Recent experimental data demonstrate a protective effect of MMF against the development of graft vasculopathy (4, 5) . Therefore, all long-term heart-transplant recipients at our center were routinely switched from azathioprine to MMF.
MMF is the 2,4-morpholino-ethylester of mycophenolic acid (MPA)-a noncompetitive reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). The inhibition of IMPDH-the rate-limiting enzyme in the de novo pathway of guanine nucleotide synthesis-directly reduces intracellular guanine nucleotide pools in vitro (6 -8) . Lymphocyte clonal expansion is especially dependent on de novo purine synthesis. The salvage pathway, although present in proliferating lymphocytes, cannot by itself provide the required rate of guanine nucleotide production under physiologic conditions.
Clinical pharmacokinetic monitoring is a well-established practice to optimize immunosuppression in an individual way. However, inter-and intraindividual variability in primary kinetic processes, enterohepatic recirculation, and changes in MPA pharmacokinetics over time lead to inconsistency in the concentration achieved from a given dosage of MMF (9 -11) . The data from a recent prospective randomized study demonstrate no relationship between predose MPA concentration and clinical efficacy and drug-related adverse events of MMF (12) . Hence, the measurement of trough blood concentration provides only a poor idea of the level of immunosuppression attained in an individual patient.
An alternative approach to assess the degree of pharmacological activity of immunosuppressive agents is the measurement of the biological response to the drug. Pharmacodynamic monitoring of MMF is performed by measurement of catalytic activity of the enzyme target of the drug, IMPDH, in whole blood and lymphocytes.
All published studies showed inverse correlation between plasma MPA concentration and IMPHD catalytic activity (13) (14) (15) (16) (17) . On the other hand, investigations have shown significant changes in pharmacodynamic behavior of MMF over time (17, 18) . Decrease of inhibitory activity of MPA and even induction of IMPDH after long-term MMF therapy was discussed (17) .
At present, IMPDH monitoring in patients receiving MMF is still investigational, reported data based on either a very small number of patients or IMPDH activity was measured in cells, which are not a primary target of the drug.
We studied the in vivo pharmacodynamics of MPA in stable heart recipients routinely switched from azathioprine to MMF. Intracellular GTP and ATP levels and activities of IMPDH and purine salvage pathway enzymes guanine phosphoribosyltransferase (GPRT) and hypoxanthine phosphoribosyltransferase (HPRT) were measured in PBMC over 1 year. Additionally, MPA plasma trough level was monitored during the entire observation period.
PATIENTS AND METHODS
All long-term heart-transplant recipients at our center were routinely switched from azathioprine to MMF. Out of these, 30 stable patients (time since transplantation 7.1Ϯ3.9 years) were enrolled in this trial. Three patients were excluded from the study between 1 and 9 months after switch because of adverse drug-related effects (gastrointestinal disturbances). The data of 27 patients was used for further analysis. Demographics are shown in Table 1 .
All patients received induction therapy with polyclonal rabbit antihuman thymocyte immunoglobulin (Thymoglobuline, Sangstat) 2.0 mg/kg body weight i.v. for 3 to 7 days immediately after transplantation. Maintenance immunosuppressive regimen consisted of cyclosporine A with a target level of 75-300 ng/ml (c 0 , monoclonal, FPIA) depending on the time after transplantation, corticosteroids (initial dosage 0.2 mg/kg/day with subsequent taper to 0.1 mg/kg/day within 2 months after transplantation), and azathioprine (1.5 mg/kg initially). Azathioprine dosage was adapted to achieve a leukocyte count between 4000 and 6000 G/L. Median azathioprine dosage in study participants before switch to MMF was 75 mg (25-150 mg) daily. At the start of the trial, patients were switched from azathioprine to MMF within 2 days with a MMF dosage of 500 mg twice daily. Dosage and dosing regimen were kept constant during the study period.
Sample Collection
After giving informed consent, venipuncture was performed in the outpatient clinic during the routine control visit. Collection of blood samples was performed on fasting condition 12 hours after last intake of MMF (trough concentrations) before the switch to MMF and 3, 6, and 12 months thereafter.
The control group consisted of 15 healthy volunteers (47.4Ϯ9.2 years old, 5 female). Collection of blood samples was performed in the outpatient clinic on fasting condition. For investigating day-to-day variabilities of enzyme activities, blood samples were drawn on 3 consecutive days.
Chemicals
Inosine 
Isolation of PBMC
PBMC were isolated from EDTA blood of study participants using a Ficoll-Hypaque density gradient centrifugation. The PBMC fraction was collected and washed twice with cold saline containing the protease inhibitors aprotinin (1 g/ml), leupeptin (1 g/ml), and PMSF (0.5 mmol/L). After resuspending the cells, aliquots of cell suspensions were used for cell counting in an automated counter (Microdiff, Coulter). For the determination of enzyme activities and intracellular nucleotide content, cells were diluted with either distilled water containing the mix of protease inhibitors as above (enzyme activities) or 0.2 mol/L HClO 4 (nucleotide content) to a final concentration of 1ϫ10 7 /100 L. Acidic cell lysates were neutralized with 0.5 mol/L K 2 HPO 4 . All extracts were immediately frozen at -80°C.
Determination of Intracellular Nucleotide Pools by HPLC
ATP and GTP were separated injecting 100 l of the neutralized supernatant onto a HiChrom P10SAX-3191 column (Hichrom Ltd., Berkshire, UK) with a KH 2 PO 4 gradient. Buffer A consisted of 0.015 mol/L KH 2 PO 4 (pH 3.45), buffer B of 0.5 mol/L KH 2 PO 4 (pH 3.45). A linear gradient rising from 0% B to 100% B in 45 min was used with a total run time of 65 min and an equilibrium delay of 10 min. The flow rate was 1 ml/min and the detection was made at 254 nm. The amounts of ATP and GTP were determined by the ratio of the peak areas in relation to the corresponding standards measured under the same conditions. The linear range for both nucleotides was between 0.5 and 1000 mol/L. The intraassay and interassay CVs were 8.3 and 11.2%, respectively. Results are given as nmol/10 6 cells. Determination of IMPDH Activity IMPDH activity was measured by means of HPLC using a modified procedure described by Griesmacher et al. (19) . The incubation buffer consisted of 80 mmol/L Na 2 HPO 4 , 200 mmol/L KCl, 500 mol/L NAD ϩ , and 500 mol/L IMP (pH 7.4). PBMC were thawed and centrifuged for 3 min at 20,000g and 4°C. The reaction was started by addition of 25 l of aqueous cell lysate and carried out for 120 min at 37°C. This reaction time was chosen since it was proven to be optimal under the assay conditions and is in line with findings by Daxecker et al. (20) . The incubation was stopped by addition of 6 l of a 2.5 mol/L HClO 4 and neutralized with 12.5 l of 3 mol/L K 2 HPO 4 . After centrifugation the supernatant was subjected to HPLC analysis. IMP, XMP, and GMP were separated by injecting 100 L of the neutralized supernatant onto a HiChrom P10SAX-3191 column with a KH 2 PO 4 gradient. Buffer A consisted of 0.015 mol/L KH 2 PO 4 (pH 3.45), buffer B of 0.5 mol/L KH 2 PO 4 (pH 3.45). A gradient rising from 0% B to 32% B in 8 min (flow rate: 1 ml/min), from 32% B to 38% B in further 8 min (flow rate: 0.5 ml/min) and back to 0% B (flow rate: 1 ml/min) was used with a total run time of 22 min and an equilibrium delay of 5 min. The nucleotide concentrations were determined at a wavelength of 254 nm. The amounts of formed GMP and XMP were determined by the ratio of their peak areas in relation to calibrators measured under the same conditions. The linear range for GMP and XMP was between 1 and 1000 mol/L. The intra-assay and interassay CVs for the measurement of IMPDH activity were 9.5 and 13.4%, respectively. IMPDH activity is given as pmol/10 6 cells per hour.
Determination of GPRT and HPRT Activity PBMC were thawed and centrifuged for 3 min at 20,000g and 4°C. Twenty microliters of the supernatant were first diluted with 20 L of an incubation buffer (0.05 mol/L MgCl 2 and 0.5 mol/L Tris-Cl; pH 7.4). After addition of 20 l of 5-phosphoribosyl-1-pyrophosphate (5 mmol/L) and 20 l of either 400 mol/L hypoxanthine (for HPRT) or 400 mol/L guanine (for GPRT) samples were incubated for 30 min at 37°C. Reactions were stopped by adding 3.5 l of a 2.5 mol/L HClO 4 acid and neutralized with 9 l of 3 mol/L K 2 HPO 4 . After centrifugation the supernatants were withdrawn and analyzed by HPLC as described for IMPDH. The amounts of formed GMP and IMP were determined by the ratio of their peak areas in relation to calibrators measured under the same conditions. The linear range for GMP and IMP was between 1 and 1000 mol/L. The intra-assay and interassay CVs for the measurement of HPRT activity were 9.1 and 12.9%, and for GPRT activity 8.7 and 11.3%. Results are expressed as nanomoles IMP (HPRT) and GMP (GPRT) per 10 6 cells per hour.
Determination of MPA Trough Level
Mycophenolic acid trough levels were determined by means of HPLC following solid-phase extraction as described earlier (21) . The determination of plasma concentrations of mycophenolic acid was subjected to batch analysis. The accuracy of the measurements was assessed and accepted by the international proficiency testing program (www.bioanalytics. co.uk/html/mycophenolic_acid_scheme.html, David Holt, ASI Ltd., Caterham, England).
Statistical Analysis
All measurements were performed in duplicate. Parametric data are presented as mean Ϯ SD, nonparametric as median and range. The difference of the enzyme activities and intracellular concentrations of guanine nucleotides between the patients before the switch to MMF and healthy volunteers was tested with a Wilcoxon two sample test and adjusted for multiple comparisons with a Bonferroni-Holm correction. To assess the power of calculation a two-sample t test with unequal variances (Welch approximation) was applied, which showed the possibility to detect the difference of 190 pmol/10 6 PBMC/h in IMPDH activity between the controls and patients before the switch with a power of 0.8.
As the differences between the time points of measurement of IMPDH activity were normally distributed, the data were analyzed by paired t test. For GPRT activities a signed rank test was used to compare the differences in time because of non-normal distribution. HPRT activities, MPA trough levels, GTP and ATP concentrations were log transformed, and these normally distributed repeated measures data were assessed by employing a general linear mixed model (SAS procedure MIXED) with a heterogeneous compound symmetry covariance pattern. The comparisons were performed consequently with and without outliers. A p value less than 0.05 was considered to indicate statistical significance. Calculations were performed using the SAS software system 9.1 (SAS Institute Inc., 2002, Cary, NC).
The correlations between the de novo and salvage pathway enzymes were corrected for multiple observations and correlation with subjects (22) .
RESULTS
Three patients were withdrawn from MMF because of gastrointestinal side effects (diarrhea in two cases, nausea in one case) and were excluded from the study. Twenty-seven patients remaining in the trial tolerated the drug well and demonstrated no clinical impairments after switch to MMF during the entire observation period.
No statistically significant alterations in intracellular concentrations of GTP and ATP in PBMC were observed between the healthy controls and patients before switch to MMF as well as during the entire observation period ( Table 2) .
The MPA trough levels remained similar over one year of MMF treatment (Fig. 1) .
There was no difference between IMPDH activity measured by azathioprine-treated patients before switch to MMF: 897 (432-1560) pmol/10 6 PBMC/h, and IMPDH activity de- Data are median (range).
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termined by healthy controls: 795 (497-1050) pmol/ 10 6 PBMC/h (Pϭ0.31). Day-to-day variability for IMPDH assessed in healthy subjects was 13.8%.
Three months after onset of MMF therapy a significant reduction (PϽ.0001) of enzyme activity showing only 316 (0 -1387) pmol/10 6 PBMC/h was registered (Fig. 2) . Six months after onset of MMF therapy this trend was confirmed with almost complete inhibition of IMPDH: 0 (0 -245) pmol/ 10 6 PBMC/h (PϽ.0001). However, IMPDH activity partially restored to 143 (0 -362) pmol/10 6 PBMC/h 1 year after onset of MMF therapy. This is significantly lower than the initial value (PϽ.0001), but also higher than the activity after 6 months (PϽ.0001).
The activities of GPRT and HPRT were also not different between the control group and azathioprine-treated patients: 8.6 (7.2-9.6) nmol/10 6 PBMC/h vs. 7.1 (5.2-14.6) PBMC/h (Pϭ0.17), respectively. Day-to-day variabilities of GPRT and HPRT as investigated in control group were 12.5% and 13.1%, respectively.
The changes of the purine salvage pathway enzymes activities GPRT and HPRT in PBMC during MMF treatment were inversely proportional to those of IMPDH. We found an increase of GPRT activity from 7.1(5.2-14.6) nmol/ 10 6 PBMC/h before MMF onset to 12.0 (6.8 -39.4) nmol/ 10 6 PBMC/h at 3 months of MMF therapy (PϽ.0001). It remained as high as 11.1 (5.7-28.6) nmol/10 6 PBMC/h at 6 months (PϽ.0001) and decreased to 9.4 (6.2-20.2) nmol/ 10 6 PBMC/h at 12 months of MMF therapy remaining significantly higher in comparison to the initial value (PϽ.0001, Fig. 3) .
The changes of HPRT activities followed in general those of GPRT (Fig. 4) . We registered an increase of enzyme activity from 16.0 (11.0 -23.8) nmol/10 6 PBMC/h preswitch to 18.3 (14.0 -28.2) nmol/10 6 PBMC/h 3 months after onset of MMF (Pϭ0.002) and to 19.4 (13.7-32.6) nmol/ 10 6 PBMC/h after 6 months (Pϭ0.001). One year after switch to MMF therapy the activity of HPRT declined to 17.9 (13.3-26.3) nmol/10 6 PBMC/h, which was not different from the initial value (Pϭ0.07).
Calculation of correlations revealed a significant inverse correlation between IMPDH activity and GPRT activity with a correlation coefficient of -0.378 (Pϭ0.0015) and between IMPDH activity and HPRT activity with a correlation coefficient of -0.389 (Pϭ0.004).
DISCUSSION
The present study is a prospective observational trial with stable HTx patients after switch from azathioprine to MMF in an attempt to investigate changes of MPA pharmacodynamics over time and their impact on purine nucleotide metabolism. We found that intracellular levels of GTP and ATP in PBMC did not change after conversion during the one year period, while morning (predose) IMPDH activity significantly declined after switch to the IMPDH inhibitor MPA. The novel and important finding is that MMF treatment leads to an induction of the salvage pathway enzymes GPRT and HPRT possibly accounting for the maintenance of GTP levels in PBMC.
The immunosuppressive effect of MPA results from a reversible uncompetitive blockade of IMPDH with subsequent inhibition of de novo nucleotide synthesis and RNA/ DNA formation in proliferating lymphocytes (6, 10) . MPA administered at immunosuppressive doses was shown to decrease the intracellular pool of GTP in PBMC in vitro (6).
Langman et al. (15) described an inverse relationship between MPA concentrations and IMPDH activity in whole blood and isolated lymphocytes of five renal recipients. The concentration of MPA at 1 hr following an oral dose resulted in approximately 40% inhibition of IMPDH, and the authors found that as MPA concentration decreased throughout the dosing interval, IMPDH activity was restored. They also demonstrated a large variation of enzyme activity and significant reduction of intracellular concentrations of GMP and GDP in lymphocytes, but no impact on GTP level.
Important changes in the pharmacodynamic effects of MMF over time were shown in patients chronically treated with MMF. Although a loss of inhibitory activity of MPA was discussed, only few and incomplete data are available. Sanquer et al. showed a two-to fivefold increase of IMPDH activity in whole blood following the MPA c max compared to baseline in patients under long-term MMF therapy, whereas in the short-term therapy group only a gradual increase of enzyme activity was revealed (17) . The authors concluded that MMF might induce IMPDH activity over time and postulated that this may be associated with the development of resistance. However, this study included a limited number of patients, and comparisons were performed between the different patients after short-and long-term MMF treatment. Nevertheless, taking into account the high interindividual variability of MPA pharmacodynamics and difficulties associated with radiochemical analysis of IMPDH activity, a lot of questions remain.
Weigel et al. demonstrated the elevation of GTP levels in erythrocytes of cardiac recipients after long-term administration of MMF as a result of an induction of IMPDH (18) . In this study, the activities of GPRT and HPRT in red blood cells were also investigated. The authors described the induction of salvage pathway enzymes one year after switch to MMF compared to the preswitch rate. However, these findings relate to anucleate cells and the comparison was performed only 1 year after switch.
We investigate MPA pharmacodynamics and their impact on purine metabolism in PBMC of patients chronically treated with MMF. To our knowledge, this is the first study that examined activities of both de novo and salvage pathway enzymes in PBMC during MMF therapy.
It has been suggested that metabolites of azathioprine may cause some degree of IMPDH inhibition (23) . To rule out this potential bias, healthy volunteers served as controls. The activities of all three enzymes did not differ between azathioprine-treated (preswitch) patients and controls. Therefore, the induction of salvage pathway enzyme activities might be an effect related to MMF therapy and not a consequence of the termination of azathioprine with consecutive restoration of enzyme activities.
Our study was performed in a prospective way in an adequate number of stable heart transplant recipients. Chronic immunosuppression without any changes lets excluding the influence of other immunosuppressive drugs on cell metabolism after switch to MMF. Significant inverse correlations between the activity of IMPDH and salvage pathway enzymes supported our hypothesis about restoration of intracellular nucleotide synthesis if one of pathways is blocked by reactivation of the other.
Despite of high interpatient variability, the results are presented with high statistical significance and day-to-day fluctuations of enzyme activities are also acceptable. All measurements were performed directly in PBMC, a vast majority of which are lymphocytes-the target cells of MPA. Because the synthesis of guanine nucleotides is also regulated by the balance between ATP and GTP pools, we investigated the intracellular ATP concentrations as well.
However, the direct measurement of enzyme activities in PBMC has some possible shortcomings: 1) activated T cells represent only a very small part of PBMC, but play a pivotal role in organ rejection; 2) the majority of PBMC are resting lymphocytes, which contain mainly type I IMPDH. Activated T cells express the type II isoform of IMPDH, which exhibits a fourfold increased sensitivity to MPA than isoform I (6); 3) free MPA only has been shown to be the pharmacologically active portion of MMF. Average bound fraction of MPA to plasma albumin is as extensive as 97.5% in individuals with normal renal function (6) , and less than 1% is located inside the mononuclear fraction. Therefore, the clinical effect of MMF is probably related to the capacity of plasma to maintain a release of free MPA to activate lymphocytes; 4) The maximum of IMPDH inhibition develops at the time of MPA c max . We performed predose blood sampling, which also could influence the results.
Our data reveal that the in vivo pharmacodynamic properties of MPA undergo significant changes over time. Partial restoration of enzyme activity after 1 year of MMF therapy makes the pharmacodynamic monitoring of immunosuppressive effects based on IMPDH activity measurements questionable. The ability of a cell as a stable biological unit to restore metabolism under changing conditions was demonstrated once again and should be taken into account. Intracellular formation of guanine nucleotides remains unchanged during MMF therapy. This suggests that the in vivo effects and mechanisms of action of MPA need to be re-assessed in the future.
